FEMSelect Announces Close of Oversubscribed Series B Equity Financing to Drive Commercial Growth, Leadership Transformation, and Global Expansion
FEMSelect, a privately held women-led company revolutionizing pelvic organ prolapse treatment with its groundbreaking EnPlace technology, announced significant advancements as part of its strategic roadmap to become a global leader in women’s health. The company’s recent oversubscribed equity financing, will accelerate its initiatives, including leadership enhancements, a U.S. headquarters relocation, and expanded commercialization efforts. The round was led by existing investors New Age Ventures and Triventures, had participation from existing investors like Robin Hood Ventures and RAD Biomed and attracted new investors Nordwand Capital, Avea Ventures, and Terra Verde Comp, reflecting strong confidence in FEMSelect’s vision and potential.
Health Technology Insights: ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer
“With participation from long-time and new investors, this influx of capital marks a major leap forward in our mission to redefine care for millions of underserved women worldwide,” said Renee Selman, Executive Chairwoman of the Board. “With a strengthened leadership team, expanded financial firepower, and a powerful product pipeline, FEMSelect is poised to accelerate growth and lead the way in transformative women’s health solutions.”
Leadership Transformation
FEMSelect is thrilled to announce the appointment of Sasha Schrode as Chief Executive Officer. With her extensive experience in healthcare, Schrode brings a wealth of knowledge and a proven track record of driving innovation and growth. Under her leadership, FEMSelect is poised for significant expansion, with plans to bolster its commercial team and diversify its product portfolio. “FEMSelect has the power to transform women’s healthcare, and I’m thrilled to help bring this breakthrough to millions worldwide,” said Sasha Schrode. “Unlike traditional surgery—which often involves extensive dissection, longer recovery, and higher risk—the EnPlace procedure is minimally invasive, requires no dissection, and allows most women to go home the same day and resume their lives quickly.” She joins FEMSelect after her successful leadership at Serpex Medical, which culminated in a strategic acquisition.
Health Technology Insights: Fujifilm Expands Partnership with NRHA to Enhance Medical Imaging Access in Rural Areas
Debbie Garner has been appointed President of FEMSelect, where she will spearhead the company’s expansion efforts in the United States and internationally. This strategic move positions FEMSelect to capitalize on emerging opportunities and strengthen its presence in key regions worldwide.
FEMSelect is also pleased to report that Rakesh Tailor, CEO of Contura International, was appointed to the Board of Directors. Given his experience in women’s health and having led the development Bulkamid and its sale to Axonics in 2021, his strategic insight will help propel the company’s presence in the U.S. and international markets.
Strategic Relocation to the U.S.
As part of its growth strategy, FEMSelect is relocating its headquarters from Israel to the United States, aligning the company closer to its largest market and expanding opportunities for strategic partnerships.
Health Technology Insights: Moleculin Gets EMA Approval to Expand Phase 3 MIRACLE Trial
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
